Log in to search using one of your social media accounts:

 

‘Oral Chemo Starter Kits’ Boosted Safe Handling on Non-Oncology Units
After non-oncology units received comprehensive safety kits for handling oral hazardous drugs, chemo handling precautions at Maine Medical Center increased significantly. (Source: CancerNetwork)
Source: CancerNetwork - May 18, 2018 Category: Cancer & Oncology Authors: Lori Smith, BSN, MSN, CRNP Tags: News Novel Drugs Oncology Nursing Conferences/ONS Source Type: news

Daily CHG Bathing Initiatives Reduced CLABSI
Detailed education and other initiatives related to CHG cloth use boosted bathing compliance rates by 95% in 14 months, and decreased CLABSI by 8%. (Source: CancerNetwork)
Source: CancerNetwork - May 18, 2018 Category: Cancer & Oncology Authors: Lori Smith, BSN, MSN, CRNP Tags: Infection Oncology Nursing Conferences/ONS Source Type: news

CBT, Acupuncture Combat Insomnia in Cancer Survivors
A study led by Dr. Jun Mao of MSKCC found CBT and acupuncture each yielded clinically meaningful and durable sleep-related QOL improvements. (Source: CancerNetwork)
Source: CancerNetwork - May 18, 2018 Category: Cancer & Oncology Authors: John Schieszer Tags: Conferences/ASCO Cognitive Behavioral Therapy Integrative Oncology News Source Type: news

Trabectedin Plus PLD Shows Benefit in Real-Life Ovarian Cancer Setting
Trabectedin plus pegylated liposomal doxorubicin offered clinical benefit in a real-life setting of patients with previously treated platinum-sensitive recurrent ovarian cancer. (Source: CancerNetwork)
Source: CancerNetwork - May 17, 2018 Category: Cancer & Oncology Authors: Dave Levitan Tags: Gynecologic Cancers SiteTerms/www.cannabissciencetech.com/News Ovarian Cancer Source Type: news

Shorter-Duration Trastuzumab as Effective for HER2+ Early Breast Cancer
Women with HER2-positive early breast cancer achieved similar disease-free survival with 6 months of adjuvant trastuzumab compared with a 12-month duration, according to the phase III PERSEPHONE trial. (Source: CancerNetwork)
Source: CancerNetwork - May 17, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Conferences/ASCO Breast Cancer HER2-Positive Breast Cancer SiteTerms/www.cannabissciencetech.com/News Source Type: news

Mathematical Modeling May Guide Cancer Treatment & #039;Holidays & #039;
A Moffitt team suggests mathematical modeling may guide the optimal cancer treatment dosing approach better than MTD. (Source: CancerNetwork)
Source: CancerNetwork - May 16, 2018 Category: Cancer & Oncology Authors: John Schieszer Tags: Breast Cancer Melanoma News Source Type: news

Auto HCT and Matched Sibling Transplant Effective in FL
While HCT is an important benefit for FL patients, the optimal approach remains up for debate. (Source: CancerNetwork)
Source: CancerNetwork - May 16, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Follicular Lymphoma News Source Type: news

Multi-epitope T-cell Vaccine Shows Promise in Ovarian, Breast Cancer
TPIV200 stimulates T cells to attack ovarian and triple negative breast tumor cells that over-express the folate receptor alpha protein. (Source: CancerNetwork)
Source: CancerNetwork - May 16, 2018 Category: Cancer & Oncology Authors: By John Schieszer Tags: Breast Cancer Immuno Oncology News Ovarian Cancer Source Type: news

Sarcopenia Predicts Tumor Recurrence Post Liver Transplantation?
Recurrence risk was greater in sarcopenic patients, and greater alpha-fetoprotein and microvascular invasion were independent risk factors. (Source: CancerNetwork)
Source: CancerNetwork - May 16, 2018 Category: Cancer & Oncology Authors: John Schieszer Tags: Liver, Gallbladder, and Biliary Tract Cancers News Source Type: news

ONS Role in New Guideline for irAE Management
In this podcast, Kelly Brassil, PhD, RN, discusses irAEs and ONS ’s role in developing an ASCO/NCCN guideline for their management. (Source: CancerNetwork)
Source: CancerNetwork - May 16, 2018 Category: Cancer & Oncology Authors: Kelly Brassil, PhD, RN Tags: News Conferences/ONS Source Type: news

Duke Team Addresses Barriers to Oral Chemo
A streamlined nursing protocol reduced delays related to treatment with oral formulations of chemotherapy and immunotherapy, and increased patient satisfaction. (Source: CancerNetwork)
Source: CancerNetwork - May 16, 2018 Category: Cancer & Oncology Authors: Lori Smith, BSN, MSN, CRNP Tags: News Conferences/ONS Source Type: news

Improving Adherence to Endocrine Therapy in Women With HR-Positive Breast Cancer
Here, we discuss how to improve adherence to endocrine therapy in women with HR-positive breast cancer, as well as the side effects and the reasons for discontinuation. (Source: CancerNetwork)
Source: CancerNetwork - May 15, 2018 Category: Cancer & Oncology Authors: Charles L. Shapiro, MD Julia P. Brockway, MD Tags: Breast Cancer Oncology Journal Source Type: news

Initiation of ADT in a Man With Locally Advanced Prostate Cancer and Multiple Cardiovascular Risk Factors
A 65-year-old man presented with locally advanced, high-risk prostate cancer. His medical history was remarkable for type 2 diabetes mellitus, and he was an active smoker with a 27 pack-year history. (Source: CancerNetwork)
Source: CancerNetwork - May 15, 2018 Category: Cancer & Oncology Authors: Francisco J. Castro-Alonso, MD Guillermo Rosales-Sotomayor Jennifer Dominguez-Pineda, MD Mar ía T. Bourlon, MD, MS Thomas W. Flaig, MD Tags: Genitourinary Cancers Oncology Journal Prostate Cancer Source Type: news

Robert Chapkin on Relationships Between the Gut Microbiome, Diet, and Colorectal Cancer
In this Q&A, we discuss the research into the relationships between gut microbiota, diet, and colorectal cancer. (Source: CancerNetwork)
Source: CancerNetwork - May 15, 2018 Category: Cancer & Oncology Authors: Robert S. Chapkin, MSc, PhD Tags: Colorectal Cancer Gastrointestinal Cancer Oncology Journal Source Type: news

Implications of Mutation Profiling in Myeloid Malignancies —PART 2: Myeloproliferative Neoplasms and Other Myeloid Malignancies
In this second part of our two-part review, we discuss the use of mutation profiling in the diagnosis, prognosis, and treatment of patients with myeloproliferative neoplasms and other myeloid diseases. (Source: CancerNetwork)
Source: CancerNetwork - May 15, 2018 Category: Cancer & Oncology Authors: Douglas Tremblay, MD John O. Mascarenhas, MD Kelsey Sokol, MD Raajit Rampal, MD Sheena Bhalla, MD Tags: Hematologic Malignancies Myeloproliferative Neoplasms Oncology Journal Review Article Source Type: news

Combination Controversies: Checkpoint Inhibition Alone or in Combination for the Treatment of Melanoma?
In this review, we highlight prospective data on checkpoint inhibition alone and in combination, discuss data regarding the efficacy and toxicity of combination therapy, and identify clinical scenarios that may favor treatment with combination therapy. (Source: CancerNetwork)
Source: CancerNetwork - May 15, 2018 Category: Cancer & Oncology Authors: Allison Betof Warner, MD, PhD Michael A. Postow, MD Tags: Melanoma Oncology Journal Review Article Source Type: news

COUNTERPOINT: Chemotherapy vs Abiraterone for the Initial Management of Metastatic Prostate Cancer
Abiraterone has become the first-choice treatment for men with metastatic prostate cancer. (Source: CancerNetwork)
Source: CancerNetwork - May 15, 2018 Category: Cancer & Oncology Authors: Robert J. Jones, MBChB, PhD Tags: Genitourinary Cancers Oncology Journal Prostate Cancer Source Type: news

POINT: Chemotherapy vs Abiraterone for the Initial Management of Metastatic Prostate Cancer
Chemotherapy is the best option for the initial management of metastatic prostate cancer. (Source: CancerNetwork)
Source: CancerNetwork - May 15, 2018 Category: Cancer & Oncology Authors: Mario A. Eisenberger, MD Pedro Isaacsson Velho, MD Tags: Genitourinary Cancers Oncology Journal Prostate Cancer Source Type: news

CDK4/6 Inhibitors: Game Changers in the Management of Hormone Receptor –Positive Advanced Breast Cancer?
Here, we review the current use of and potential next directions for CDK4/6 inhibitors in the treatment of patients with HR-positive breast cancer. (Source: CancerNetwork)
Source: CancerNetwork - May 15, 2018 Category: Cancer & Oncology Authors: Maria Raquel Nunes, MD Mirat Shah, MD Vered Stearns, MD Tags: Breast Cancer Oncology Journal Review Article Source Type: news

Quiz: Genetics and Epidemiology of Diffuse Large B-Cell Lymphoma
Can you name biomarkers that are associated with PCNS-DLBCL? Are you aware of contraindications for use of rituximab in DLBCL? Test your knowledge by taking this multiquestion quiz. (Source: CancerNetwork)
Source: CancerNetwork - May 15, 2018 Category: Cancer & Oncology Authors: Bryant Furlow Tags: Hematologic Malignancies Quiz Source Type: news

Single Gemcitabine Instillation Can Reduce Urothelial Cancer Recurrence
An intravesical instillation of gemcitabine following TURBT reduced the risk of recurrence in patients with suspected low-grade non –muscle-invasive urothelial cancer. (Source: CancerNetwork)
Source: CancerNetwork - May 14, 2018 Category: Cancer & Oncology Authors: Dave Levitan Tags: Bladder Cancer Genitourinary Cancers SiteTerms/www.cannabissciencetech.com/News Source Type: news

Adjuvant Chemotherapy Key to Improving OS in Rectal Cancer
Retrospective study shows 30 patients need to be treated with adjuvant therapy to prevent a death at 3 years. (Source: CancerNetwork)
Source: CancerNetwork - May 14, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Colorectal Cancer News Source Type: news

Targeting AXL Could Slow Metastasis in HER2-Positive Breast Cancer
New research has found that expression of AXL is correlated with poor outcomes in patients with HER2-positive breast cancer. (Source: CancerNetwork)
Source: CancerNetwork - May 14, 2018 Category: Cancer & Oncology Authors: Dave Levitan Tags: Breast Cancer HER2-Positive Breast Cancer SiteTerms/www.cannabissciencetech.com/News Source Type: news

USPSTF Recommends That PSA Screening Be an Individual Decision
The US Preventive Services Task Force issued a final recommendation on prostate cancer screening, including that men aged 55 to 69 years should make an individual decision on whether or not to be screened. (Source: CancerNetwork)
Source: CancerNetwork - May 11, 2018 Category: Cancer & Oncology Authors: Dave Levitan Tags: Genitourinary Cancers SiteTerms/www.cannabissciencetech.com/News Prostate Cancer Source Type: news

Potential Role for Vaccines, Checkpoint Inhibitors in Chemoprevention of Lynch Syndrome
Researchers from MD Anderson say their study results " open the field of immunoprevention in LS to checkpoint inhibitors as an immune interception strategy. " (Source: CancerNetwork)
Source: CancerNetwork - May 11, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Colorectal Cancer Gastrointestinal Cancer News Source Type: news

CRC Polyps May Allow for Immune Checkpoint Inhibitors in Premalignant Lesions
Colorectal carcinomas in LS patients appear in background of mismatch repair (MMR) deficiency, show a unique immune profile, and response to immunotherapy. (Source: CancerNetwork)
Source: CancerNetwork - May 11, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Colorectal Cancer Gastrointestinal Cancer News Source Type: news

Dose-Dense Chemo Shows Promise as Neoadjuvant Therapy in Bladder Cancer
A neoadjuvant dose-dense regimen was active and well tolerated in patients with muscle-invasive bladder cancer, allowing downstaging of most patients before radical cystectomy. (Source: CancerNetwork)
Source: CancerNetwork - May 11, 2018 Category: Cancer & Oncology Authors: Dave Levitan Tags: Bladder Cancer Genitourinary Cancers SiteTerms/www.cannabissciencetech.com/News Source Type: news

The Stand Up 2 Cancer Colorectal Dream Team
During AACR 2018, Dr. Diaz discusses the progress of his laboratory ’s colorectal cancer research as part of the Stand Up 2 Cancer Colorectal Dream Team. (Source: CancerNetwork)
Source: CancerNetwork - May 10, 2018 Category: Cancer & Oncology Authors: Luis A. Diaz, Jr., MD Tags: Conferences/AACR Street Team News Source Type: news

RCC Agent Lenvatinib of Benefit in Anaplastic Thyroid Cancer
Certain genetic alterations associated with anaplastic transformation in thyroid cancer made patients sensitive to the multikinase inhibitor lenvatinib. (Source: CancerNetwork)
Source: CancerNetwork - May 10, 2018 Category: Cancer & Oncology Authors: John Schieszer Tags: Thyroid Cancer Source Type: news

Osimertinib Improves Patient-Reported Outcomes in Advanced NSCLC
An analysis of patient-reported outcomes showed that osimertinib yielded a longer time to deterioration compared with chemotherapy in patients with advanced non –small-cell lung cancer. (Source: CancerNetwork)
Source: CancerNetwork - May 10, 2018 Category: Cancer & Oncology Authors: Dave Levitan Tags: Lung Cancer SiteTerms/www.cannabissciencetech.com/News Source Type: news

Patient and Tumor Features Predicted RCC Outcomes Post Nephrectomy
Routinely available patient and tumor features accurately predicted the risk progression and death from RCC post nephrectomy, a Mayo Clinic team found. (Source: CancerNetwork)
Source: CancerNetwork - May 9, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Genitourinary Cancers News Renal Cell Carcinoma Source Type: news

Discovery of Genes Linked to Myeloma Onset May Drive Personalized Tx
A UK team found multiple targets of non-coding mutations, highlighting the importance of broadening the search for cancer drivers into the regulatory genome. (Source: CancerNetwork)
Source: CancerNetwork - May 9, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Hematologic Malignancies Multiple Myeloma News Source Type: news

Dabrafenib/Trametinib Combination Approved in BRAF-Mutant Melanoma
The FDA granted approval to the combination of dabrafenib and trametinib for the adjuvant treatment of melanoma, specifically in patients with a BRAF V600E or V600K mutation. (Source: CancerNetwork)
Source: CancerNetwork - May 9, 2018 Category: Cancer & Oncology Authors: Dave Levitan Tags: Melanoma SiteTerms/www.cannabissciencetech.com/News Source Type: news

CAR T-Cell Tx Tisagenlecleucel Approved for DLBCL
The approval includes adults with R/R DLBCL after two or more lines of prior systemic therapy, high-grade B-cell lymphoma, and DLBCL arising from FL. (Source: CancerNetwork)
Source: CancerNetwork - May 8, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Diffuse Large B-Cell Lymphoma Hematologic Malignancies News Source Type: news

Lab Study Shows HER2 Inhibitor Lapatinib Can Induce Cell Proliferation
A laboratory study has found that the HER2 inhibitor lapatinib used to slow HER2-positive breast cancer can actually induce tumor growth in some circumstances. (Source: CancerNetwork)
Source: CancerNetwork - May 8, 2018 Category: Cancer & Oncology Authors: Dave Levitan Tags: Breast Cancer HER2-Positive Breast Cancer SiteTerms/www.cannabissciencetech.com/News Source Type: news

Maintenance Bortezomib: No Improved Depth of Response in “Plateaued” MM
Investigators concluded further investigations are warranted in elderly patients with either stable or responsive disease after bortezomib induction therapy. (Source: CancerNetwork)
Source: CancerNetwork - May 8, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Immuno Oncology Multiple Myeloma News Source Type: news

Maintenance Bortezomib: No Improved Depth of Reponse in “Plateaued” MM
Investigators concluded further investigations are warranted in elderly patients with either stable or responsive disease after bortezomib induction therapy. (Source: CancerNetwork)
Source: CancerNetwork - May 8, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Immuno Oncology Multiple Myeloma News Source Type: news

NSAID Use Associated With Shorter PFS, OS in Metastatic RCC
A pooled retrospective analysis of nearly 5,000 mRCC patients in phase II and III trials showed PFS among NSAIDs users was half that of NSAIDs nonusers. (Source: CancerNetwork)
Source: CancerNetwork - May 7, 2018 Category: Cancer & Oncology Authors: John Schieszer Tags: News Renal Cell Carcinoma Source Type: news

CD40-Activating Monoclonal Antibodies Boost Response to Immunotherapy
Activating CD40 is “a key to initiating a T-cell response to tumors,” says Dr. Robert Vonderheide, MD, director of U Penn’s Abramson Cancer Center. (Source: CancerNetwork)
Source: CancerNetwork - May 7, 2018 Category: Cancer & Oncology Authors: John Schieszer Tags: Immuno Oncology News Source Type: news

Immune Checkpoint Inhibitors Safe, Effective in Older Cancer Patients
A retrospective study of ICIs by French investigators found manageable toxicity in patients over age 70, and survival outcomes comparable to younger patients. (Source: CancerNetwork)
Source: CancerNetwork - May 4, 2018 Category: Cancer & Oncology Authors: John Schieszer Tags: Immuno Oncology News Older Patients Source Type: news

Online Tool for Reporting Prostate Cancer Comorbidities Shows Promise
An at-home online survey was found to be a reasonably accurate way to collect patient comorbidities prior to a physician visit in patients with prostate cancer. (Source: CancerNetwork)
Source: CancerNetwork - May 3, 2018 Category: Cancer & Oncology Authors: Dave Levitan Tags: Genitourinary Cancers SiteTerms/www.cannabissciencetech.com/News Prostate Cancer Source Type: news

Synthetic Lethality of PARP Inhibitors in Prostate Cancer
In this podcast, Dr. Emmanuel Antonarakis discusses his novel clinical trial evaluating PARP inhibitors in high-risk and biochemically recurrent prostate cancer. (Source: CancerNetwork)
Source: CancerNetwork - May 3, 2018 Category: Cancer & Oncology Authors: Emmanuel Antonarakis, MD Tags: Genitourinary Cancers News Prostate Cancer Source Type: news

Crucial Mutations Found in T-Cell ALL
T-ALL may be treatable by targeting signaling pathways affected by STIL-TAL1 fusion, according to a team from The Institute of Cancer Research, London, UK. (Source: CancerNetwork)
Source: CancerNetwork - May 3, 2018 Category: Cancer & Oncology Authors: John Schieszer Tags: Acute Lymphoblastic Leukemia News Source Type: news

New CABOSUN Data Show Better PFS With Cabozantinib in mRCC
The significantly better PFS compared with sunitinib supports cabozantinib as initial therapy for patients with advanced RCC of intermediate or poor risk. (Source: CancerNetwork)
Source: CancerNetwork - May 3, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Tags: News Renal Cell Carcinoma Source Type: news

A Sit Down With Cancer
A doctor sits down with cancer to gauge its feelings towards new immunotherapy agents, lower smoking rates, and the US obesity epidemic. (Source: CancerNetwork)
Source: CancerNetwork - May 2, 2018 Category: Cancer & Oncology Authors: Craig R. Hildreth, MD Source Type: news

False ‐Positive Screening Results Affects Patients Willingness for Follow-Up
A Cleveland Clinic team found patients with false-positive results subsequently become more involved in cancer screening programs. (Source: CancerNetwork)
Source: CancerNetwork - May 2, 2018 Category: Cancer & Oncology Authors: John Schieszer Tags: News Survivorship Source Type: news

Patients With False ‐Positive Screening Results More Amenable to Future Screening
A Cleveland Clinic team found patients with false-positive results subsequently become more involved in cancer screening programs. (Source: CancerNetwork)
Source: CancerNetwork - May 2, 2018 Category: Cancer & Oncology Authors: John Schieszer Tags: News Survivorship Source Type: news

Higher Cancer Costs for Younger Patients?
In the US, cancer treatment is more expensive for patients younger than 65, according to a Kaiser Permanente study. (Source: CancerNetwork)
Source: CancerNetwork - May 1, 2018 Category: Cancer & Oncology Authors: John Schieszer Tags: News Source Type: news

A 32-Year-Old Man With Lower Back Pain
A 32-year-old man presents with pain in the lower back of several weeks ’ duration. What is your diagnosis? (Source: CancerNetwork)
Source: CancerNetwork - May 1, 2018 Category: Cancer & Oncology Authors: Cesar A. Moran, MD Tags: Image IQ Source Type: news

NCI Genomic Analysis May Refine DLBCL Therapy
“The core message is that DLBCL can no longer be viewed as a single disease,” explained senior author Dr. Louis M. Staudt, Director of NCI’s Center for Cancer Genomics. (Source: CancerNetwork)
Source: CancerNetwork - May 1, 2018 Category: Cancer & Oncology Authors: John Schieszer Tags: Diffuse Large B-Cell Lymphoma Hematologic Malignancies News Source Type: news